Fate Therapeutics Q2 2024: Cash $352M; FT819 SLE study adds Cy; FT522 first patient without conditioning

FATE THERAPEUTICS INC

2024-Q2 EPS reported -$0.79 revenue$8,697,000

Cash, equivalents & investments $352.0M; projected operating runway through YE26.
Revenue $6.8M (incl. $5M milestone from Ono); GAAP operating expenses $51.9M (R&D $34.6M, G&A $17.3M).
FT819 Phase 1 SLE study: first patient (lupus nephritis) dosed; protocol amended to include single-agent cyclophosphamide; no Grade≥3 AEs, no CRS/ICANS/GvHD.
FT825/ONO-8250 Phase 1 solid tumor study: three patients treated as monotherapy; combo dosing with mAb expected 3Q24.
FT522 Phase 1 BCL study: first patient treated without conditioning chemotherapy at 300M cells/dose; IND for autoimmune basket study planned 3Q24.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.